BeOne Medicines **Corporate Overview**

BeOne is a global oncology company that is focused on uniting the worldwide community against cancer and delivering innovative medicines faster and more affordably to patients, wherever they live.

Our founding belief is that there is a better way to bring innovative treatments to patients around the world. After 15 years of investment in building a modern biotech company from the ground up, our world-class clinical development, research, and manufacturing capabilities are delivering industry-leading speed and cost advantages, setting new benchmarks for innovation and efficiency.

Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients.

Today, we operate in more than **40 markets** across **six continents**. **More than 1.7 million** patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.

Innovative Science Responding to the Greatest Areas of Need

We have one of the largest and most productive oncology research teams in the world, with **more than 1,100 highly-credentialed scientists** with a proven track record of developing innovative medicines that address significant unmet needs. We also have **one of the largest and most compelling oncology pipelines** in the industry.

For more information visit:

BeOneMedicines.com **@BeOneMedicines** **@BeOneMeds**

BeOne

Facts at a Glance

11k+
Colleagues globally in over **40** offices on **6** continents

$3.8B
2024 total revenue*

1.7M+
Patients treated with our medicines

40+
Assets in clinical and commercial stages

1.1k+
Oncology research team

3.7k
Clinical development team members

In-house manufacturing
including diversified global supply chain

40+
Phase 3 or potentially registration enabling trials

*As of February 27, 2025

Global Capabilities to Reach More Patients

We are challenging industry conventions with our own in-house drug discovery and development capabilities. This model has generated one of the industry's most robust oncology pipelines, allowing us to conduct **more than 170 clinical trials** among **more than 25,000 patients**, and receive regulatory approvals in **more than 70 markets** across three internally developed medicines. In 2024, our clinical operations team largely executed clinical trials in-house.

Our fully integrated manufacturing capabilities also allow us to speed-up our clinical development efforts while ensuring the highest-quality production of our clinical and commercial portfolio of small-molecule, biologics and emerging modality therapeutics.

As we work towards achieving our mission, our focus on sustainable practices improve operational resilience and safeguard business continuity.

Opened in 2024, the Princeton West Innovation Campus in New Jersey, United States houses a state-of-the art, clinical and commercial-stage biologics manufacturing facility and clinical R&D center, to complement our existing capabilities around the world.

For more information visit:

BeOneMedicines.com **@BeOneMedicines** **@BeOneMeds**

BeOne